Storia in 1 fonti

French gene therapy biotech gets €33M to follow Krystal's blueprint

Cyllene Therapeutics raised €33 million in a Series C and rebranded from EG 427 as it starts a potentially registrational Phase 2/3 next year in neurogenic detrusor overactivity.

Raccontata da

endpoints.news

Timeline cronologica

martedì 7 luglio 2026·endpoints.news
French gene therapy biotech gets €33M to follow Krystal's blueprint
Cyllene Therapeutics raised €33 million in a Series C and rebranded from EG 427 as it starts a potentially registrational Phase 2/3 next year in neurogenic detrusor overactivity.